source
- Faeth Therapeutics reports 33% response rate in phase 2 endometrial cancer combo trialFaeth Therapeutics presented topline results from its phase 2 study of an oral combination targeting the PI3K/AKT/mTOR pathway in patients with advanced or recurrent endometrial cancer. The regimen…
- Merck ends Sutro partnership on IL-2 agonist MK-1484 amid routine pipeline prioritizationMerck announced it is discontinuing development of MK-1484, an interleukin-2 agonist created in partnership with Sutro Biopharma. The drug entered clinical testing in 2022 as a monotherapy and in…